GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2009

Tocris to Market Two AstraZeneca Compounds as Preclinical Cancer Research Tools

  • Tocris Bioscience obtained exclusive rights from AstraZeneca to supply two anticancer agents, anastrozole and bicalutamide, as preclinical research compounds.  Anastrozole is an aromatase inhibitor, and bicalutamide is an androgen inhibitor.

    “By making the fully licensed products available through our catalogue, we hope to promote new and exciting research in the fundamental processes that drive cancer development,” says Duncan Crawford, Tocris’ CSO.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Moral Calculations May Shift Biobank Balances

How should consent terms reconcile donors’ moral concerns with biobanks’ research goals?